Table 5.
Multivariate associations between guideline adherence parameters and P-related and R-related determinants
| Guideline adherence parameter | OR (95% CI) | p Value | |
|---|---|---|---|
| Prescription of DMARDs in agreement with the local preferential sequence | |||
| P | Number of treatment options | 0.78 (0.63 to 0.97) | 0.03 |
| Explained variance (%) | 5.2 | ||
| Referral to a specialised nurse within the first 3 visits | |||
| P | Presence of erosive disease | 0.68 (0.16 to 0.93) | 0.03 |
| P | Comorbidity | 0.68 (0.13 to 1.00) | 0.05 |
| Explained variance (%) | 9.8 | ||
| Referral to a PA or NP within the first year of treatment | |||
| R | PhD degree or pursuing a PhD | 4.14 (1.33 to 12.86) | 0.01 |
| Explained variance (%) | 12.0 | ||
| Regular outpatient clinic visits combined a nurse-led DAS28 assessment | |||
| P | Female gender | 0.63 (0.41 to 0.97) | 0.04 |
| P | RF and/or aCCP positivity | 0.43 (0.28 to 0.66) | <0.01 |
| P | Seen by a R before (second opinion) | 0.41 (0.22 to 0.77) | 0.01 |
| Explained variance (%) | 7.9 | ||
| Correct intervals between regular outpatient clinic visits | |||
| P | Seen by a R before (second opinion) | 0.56 (0.37 to 0.85) | 0.01 |
| Explained variance (%) | 2.5 | ||
aCCP, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, disease modifying anti-rheumatic drug; NP, nurse practitioner; P, patient; PA, physician assistant; R, rheumatologist; RF, rheumatoid factor.